Okedi · DIN 02544628 · 100 mg · Pd for suspension-Syr Kit
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
No interchangeable product listed in the Ontario extract
Okedi · DIN 02544628
Manufacturer: Laboratorios Farmaceuticos Rovi; listing date 2026-09-29
Health Canada: Marketed since 2025-05-27 · brand OKEDI · ATC N05AX08 RISPERIDONE · form Kit, Powder for suspension (sustained-release · route Intramuscular · ingredients RISPERIDONE 100 MG/SYR · company Laboratorios farmaceuticos rovi, s.a. · schedule Prescription
Okedi: Formulary list price $250.00 per unit (the source does not state the unit; exact figure $250.0000). What the ministry pays, not the patient.
Ministry pays: $250.0000 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02544628)
Source record
DIN 02544628: Okedi
Raw flags: sec3=Y
Item: 920000828; group id 955; item number 2268; lccId None; manufacturer id LFR
Source form: Pd for Susp-Syr Kit; strength: 100mg
Recorded listing: General benefit
Source prices (unrounded): $250.0000; ministry $250.0000
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02544628
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103319
Therapeutic Notes (formulary)
For the treatment of schizophrenia in patients who have:
A history of non-adherence; AND one of the following:
(a) Inadequate control or significant side-effects from two or more formulary oral antipsychotic medications, including at least one atypical agent; OR
(b) Inadequate control or significant side-effects from one or more conventional depot antipsychotic agents.
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02544628
Shortage record checked October 6, 2026